Base de dados : MEDLINE
Pesquisa : E01.370.225.625.115.610 [Categoria DeCS]
Referências encontradas : 8307 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 831 ir para página                         

  1 / 8307 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465591
[Au] Autor:Wang H; Lu SC; He L; Dong JH
[Ad] Endereço:Department of Hepatobiliary Surgery, The General Hospital of the People's Liberation army.
[Ti] Título:A study on risk factors and diagnostic efficiency of posthepatectomy liver failure in the nonobstructive jaundice.
[So] Source:Medicine (Baltimore);97(8):e9963, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Liver failure remains as the most common complication and cause of death after hepatectomy, and continues to be a challenge for doctors.t test and χ test were used for single factor analysis of data-related variables, then results were introduced into the model to undergo the multiple factors logistic regression analysis. Pearson correlation analysis was performed for related postoperative indexes, and a diagnostic evaluation was performed using the receiver operating characteristic (ROC) of postoperative indexes.Differences in age, body mass index (BMI), portal vein hypertension, bile duct cancer, total bilirubin, alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), operation time, cumulative portal vein occlusion time, intraoperative blood volume, residual liver volume (RLV)/entire live rvolume, ascites volume at postoperative day (POD)3, supplemental albumin amount at POD3, hospitalization time after operation, and the prothrombin activity (PTA) were statistically significant. Furthermore, there were significant differences in total bilirubin and the supplemental albumin amount at POD3. ROC analysis of the average PTA, albumin amounts, ascites volume at POD3, and their combined diagnosis were performed, which had diagnostic value for postoperative liver failure (area under the curve (AUC): 0.895, AUC: 0.798, AUC: 0.775, and AUC: 0.903).Preoperative total bilirubin level and the supplemental albumin amount at POD3 were independent risk factors. PTA can be used as the index of postoperative liver failure, and the combined diagnosis of the indexes can improve the early prediction of postoperative liver failure.
[Mh] Termos MeSH primário: Hepatectomia/efeitos adversos
Icterícia/sangue
Falência Hepática/etiologia
Complicações Pós-Operatórias
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Área Sob a Curva
Ascite/etiologia
Bilirrubina/sangue
Índice de Massa Corporal
Distribuição de Qui-Quadrado
Criança
Pré-Escolar
Feminino
Seres Humanos
Hipertensão Portal/complicações
Hipertensão Portal/cirurgia
Lactente
Icterícia/cirurgia
Testes de Função Hepática
Neoplasias Hepáticas/complicações
Neoplasias Hepáticas/cirurgia
Modelos Logísticos
Masculino
Meia-Idade
Duração da Cirurgia
Período Pós-Operatório
Valor Preditivo dos Testes
Período Pré-Operatório
Tempo de Protrombina
Curva ROC
Estudos Retrospectivos
Fatores de Risco
Albumina Sérica/análise
Adulto Jovem
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Serum Albumin); RFM9X3LJ49 (Bilirubin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009963


  2 / 8307 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29279560
[Au] Autor:Kubomura Y; Ise Y; Wako T; Katayama S; Noro R; Kubota K
[Ad] Endereço:Section of Pharmaceutical Services, Nippon Medical School Hospital.
[Ti] Título:A Drug Interaction between Crizotinib and Warfarin in Non-Small-Cell Lung Cancer: A Case Report.
[So] Source:J Nippon Med Sch;84(6):291-293, 2017.
[Is] ISSN:1347-3409
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:We report a case of increased prothrombin time-international normalized ratio (PT-INR) when crizotinib and warfarin were co-administered. A 74-year-old Japanese woman presented to the hospital with dyspnea, and was diagnosed with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Three years after surgical resection of the tumor, the patient started crizotinib because of the recurrence of NSCLC. She received 2 mg/day warfarin due to a medical history of cerebral infarction and chronic atrial fibrillation. Before crizotinib initiation, the patient's PT-INR was 2.60. After 7 days of daily doses of crizotinib, the patient's PT-INR increased to 3.65. This case report provides the first evidence of a drug interaction between crizotinib and warfarin.
[Mh] Termos MeSH primário: Anticoagulantes/administração & dosagem
Anticoagulantes/efeitos adversos
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Coeficiente Internacional Normatizado
Neoplasias Pulmonares/tratamento farmacológico
Recidiva Local de Neoplasia/tratamento farmacológico
Inibidores de Proteínas Quinases/administração & dosagem
Inibidores de Proteínas Quinases/efeitos adversos
Tempo de Protrombina
Pirazóis/administração & dosagem
Pirazóis/efeitos adversos
Piridinas/administração & dosagem
Piridinas/efeitos adversos
Varfarina/administração & dosagem
Varfarina/efeitos adversos
[Mh] Termos MeSH secundário: Idoso
Carcinoma Pulmonar de Células não Pequenas/sangue
Interações Medicamentosas
Quimioterapia Combinada/efeitos adversos
Feminino
Seres Humanos
Neoplasias Pulmonares/sangue
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Protein Kinase Inhibitors); 0 (Pyrazoles); 0 (Pyridines); 53AH36668S (crizotinib); 5Q7ZVV76EI (Warfarin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE
[do] DOI:10.1272/jnms.84.291


  3 / 8307 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27774726
[Au] Autor:Jonsson PI; Letertre L; Juliusson SJ; Gudmundsdottir BR; Francis CW; Onundarson PT
[Ad] Endereço:Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland.
[Ti] Título:During warfarin induction, the Fiix-prothrombin time reflects the anticoagulation level better than the standard prothrombin time.
[So] Source:J Thromb Haemost;15(1):131-139, 2017 01.
[Is] ISSN:1538-7836
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Essentials Fiix-prothrombin time (PT) monitoring of warfarin measuring factor (F) II and X, is effective. Plasma obtained during warfarin induction and stable phase in Fiix-trial was assayed. Fiix-PT stabilized anticoagulation earlier than monitoring with traditional PT-INR. FVII had little effect on thrombin generation that was mainly determined by FII and FX. SUMMARY: Background The prothrombin time (PT) is equally prolonged by reduction of each of the vitamin K-dependent (VKD) factors (F) II, VII and X. The Fiix-PT is only affected by FII and FX, the main contributors to thrombin generation (TG). Objective To test the hypothesis that variability in warfarin anticoagulation is reduced early during monitoring with the normalized PT-ratio calculated from Fiix-PT (Fiix-International Normalized Ratio [INR]) compared with traditional PT-INR monitoring. Also, that because of its insensitivity to FVII, Fiix-PT more accurately reflects TG when Fiix-INR and PT-INR are discrepant. Methods Samples from Fiix-trial participants monitored with either Fiix-PT or PT were used. VKD coagulation factors and TG were measured in samples from 40 patients during stable anticoagulation and in serial samples obtained from 26 patients during warfarin induction. TG was assessed in relation to selective reduction in single VKD factors. Results During Fiix-warfarin induction full anticoagulation measured as FII or FX activity was achieved at a similar rate to that with PT-warfarin but subsequently stabilized better. Fiix-INR but not PT-INR mirrored total TG during initiation. During induction, FII (R = 0.66) and FX (R = 0.52) correlated better with TG and with a steeper slope than did FIX (R = 0.37) and in particular FVII (R = 0.21). In vitro, FII and FX were the main determinants of TG at concentrations observed during VKA anticoagulation, whereas FVII and FIX had little influence. Conclusions Fiix-PT monitoring reduces anticoagulation variability, suggesting that monitoring FVII has a limited role during VKA management. TG is better reflected by Fiix-PT.
[Mh] Termos MeSH primário: Anticoagulantes/uso terapêutico
Fator X/química
Protrombina/química
Varfarina/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Coagulação Sanguínea/efeitos dos fármacos
Fatores de Coagulação Sanguínea/uso terapêutico
Testes de Coagulação Sanguínea/métodos
Método Duplo-Cego
Monitoramento de Medicamentos
Feminino
Hemostáticos/uso terapêutico
Seres Humanos
Coeficiente Internacional Normatizado
Masculino
Meia-Idade
Tempo de Protrombina
Trombina/química
Vitamina K/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Blood Coagulation Factors); 0 (Hemostatics); 12001-79-5 (Vitamin K); 5Q7ZVV76EI (Warfarin); 9001-26-7 (Prothrombin); 9001-29-0 (Factor X); EC 3.4.21.5 (Thrombin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1111/jth.13549


  4 / 8307 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390508
[Au] Autor:Xu F; Wang C; Yin C; Jiang X; Jiang L; Wang Z; Meng F
[Ad] Endereço:Hematology Department, Nanfang Hospital, Southern Medical University, Guangzhou.
[Ti] Título:Analysis of early death in newly diagnosed acute promyelocytic leukemia patients.
[So] Source:Medicine (Baltimore);96(51):e9324, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to identify risk factors for early death (ED) in acute promyelocitic leukemia (APL) patients.Clinical records of 49 APL patients who suffered ED were divided into 4 groups: death before treatment or within the first 3 days (immediate death; iED group), death during treatment at least 3 days after commencement (ED after treatment), low/intermediate risk, and high-risk groups.White blood cell (WBC) count, high-risk cases, prothrombin time (PT) prolongation, international society on thrombosis and hemostasis (ISTH) scores (P < .05), bleeding (P = .05), and death due to severe hemorrhage (P = .010) were higher in iED group than ED after treatment. And the time from onset to initial hospitalization or death was significantly shorter (P < .05) in iED patients. LDH level (P = .002), PT prolongation (P = .014), and incidence of grades 3 or 4 bleeding (P = .049) were higher in high-risk group than in ED and low/intermediate-risk groups, while the times from onset to the initial hospitalization or death were lower for ED patients in high-risk group (P = .037).We found that different types of EDs have different clinical features. A high WBC count contributes to the occurrence of more ED, which is usually not associated with delay of diagnosis and hospitalization. Current therapeutic strategies to reduce the incidence of ED in these cases are not adequate and will benefit from focused research attention.
[Mh] Termos MeSH primário: Leucemia Promielocítica Aguda/mortalidade
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
China/epidemiologia
Feminino
Hemoglobinas/análise
Hemorragia/mortalidade
Seres Humanos
L-Lactato Desidrogenase/sangue
Leucemia Promielocítica Aguda/sangue
Contagem de Leucócitos
Masculino
Meia-Idade
Tempo de Protrombina
Fatores de Tempo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Hemoglobins); EC 1.1.1.27 (L-Lactate Dehydrogenase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009324


  5 / 8307 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29025666
[Au] Autor:Horakova J; Mikes P; Saman A; Svarcova T; Jencova V; Suchy T; Heczkova B; Jakubkova S; Jirousova J; Prochazkova R
[Ad] Endereço:Technical University of Liberec, Faculty of Textile, Department of Nonwovens and Nanofibrous Materials, Studentska 2, 461 17 Liberec, Czech Republic. Electronic address: jana.horakova@tul.cz.
[Ti] Título:Comprehensive assessment of electrospun scaffolds hemocompatibility.
[So] Source:Mater Sci Eng C Mater Biol Appl;82:330-335, 2018 Jan 01.
[Is] ISSN:1873-0191
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Biodegradable polyesters, namely polycaprolactone (PCL) and copolymer of polylactide and polycaprolactone (PLCL) were electrospun into various fibrous structures and their hemocompatibility was evaluated in vitro. Firstly, hemolytic effect was evaluated upon incubation with diluted whole blood. The results showed that the degree of hemolysis depended on chemical composition and fibrous morphology. Electrospun polycaprolactone induced slight degree of hemolysis depending on its molecular weight and fibrous morphology; copolymer PLCL did not cause detectable hemolysis. The influence of coagulation pathways was examined by measurement of coagulation times. It was showed that intrinsic coagulation pathway assessed by activated partial thromboplastin time (APTT) was moderately accelerated after incubation with PCL and prolonged after incubation with copolymer PLCL. Extrinsic activation of coagulation tested by prothrombin time (PT) was slightly accelerated after incubation with all tested electrospun samples. Thrombogenicity assessment of fibrous samples revealed high thrombogenic properties of fibrous materials that was comparable to high degree of collagen thrombogenicity. The level of platelet activation was dependent on chemical composition and surface morphology of tested materials.
[Mh] Termos MeSH primário: Materiais Biocompatíveis/química
Polímeros/química
[Mh] Termos MeSH secundário: Materiais Biocompatíveis/síntese química
Materiais Biocompatíveis/farmacologia
Células Sanguíneas/citologia
Células Sanguíneas/efeitos dos fármacos
Células Sanguíneas/metabolismo
Colágeno/química
Hemólise/efeitos dos fármacos
Seres Humanos
Microscopia Eletrônica de Varredura
Tempo de Tromboplastina Parcial
Poliésteres/química
Polímeros/síntese química
Tempo de Protrombina
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biocompatible Materials); 0 (Polyesters); 0 (Polymers); 24980-41-4 (polycaprolactone); 459TN2L5F5 (poly(lactide)); 9007-34-5 (Collagen)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171014
[St] Status:MEDLINE


  6 / 8307 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29217384
[Au] Autor:Markowicz-Piasecka M; Huttunen KM; Mikiciuk-Olasik E; Sikora J
[Ad] Endereço:Laboratory of Bioanalysis, Department of Pharmaceutical Chemistry, Drug Analysis and Radiopharmacy, Medical University of Lodz, ul. Muszynskiego1, 90-151 Lodz, Poland. Electronic address: magdalena.markowicz@umed.lodz.pl.
[Ti] Título:Biocompatible sulfenamide and sulfonamide derivatives of metformin can exert beneficial effects on plasma haemostasis.
[So] Source:Chem Biol Interact;280:15-27, 2018 Jan 25.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:As the pharmacokinetic properties of metformin are unfavourable, several analogues and prodrugs have been synthesised to improve its bioavailability. The aim of this study was to assess the plasma stability of sulfenamide and sulfonamide derivatives of metformin and establish their effects on plasma haemostasis and integrity of red blood cells (RBCs). The overall haemostasis potential was evaluated spectrophotometrically by clot formation and lysis test (CL-test). PT (Prothrombin Time) and APTT (Activated Partial Tromboplastin Time) were used to evaluate the effects if the compounds on the extrinsic and intrinsic coagulation pathway. Haemolysis assay, microscopy and flow cytometry studies were conducted to determine the effect of the compounds on RBCs. Two sulfonamide and one sulfenamide derivatives of metformin were associated with a statistically significant decrease in the overall potential of clot formation and fibrinolysis (↓ CL ), suggesting that these compounds may exert beneficial effects regarding plasma haemostasis, which is frequently impaired in diabetic patients. p- and o-Nitrobenzene sulfonamides contributed to the beneficial change in kinetic parameters of clot formation and fibrinolysis. o-Nitrobenzene sulfonamide significantly increased thrombin generation time (↑ TGt) and was also found to prolong both APTT and PT. All compounds did not exert any effects on the integrity of RBCs over the concentration range 0.006-0.6 µmol/mL which constitutes the expected therapeutic concentration. In conclusion, sulfonamide derivatives of metformin present potentially beneficial properties in terms of plasma haemostasis which is frequently impaired in T2DM patients. Therefore, metformin sulfonamides may become a prototype for further design and synthesis of novel metformin analogues and prodrugs with improved pharmacokinetic properties.
[Mh] Termos MeSH primário: Materiais Biocompatíveis/química
Hemólise/efeitos dos fármacos
Metformina/análogos & derivados
Sulfamerazina/química
Sulfanilamidas/química
[Mh] Termos MeSH secundário: Materiais Biocompatíveis/metabolismo
Materiais Biocompatíveis/farmacologia
Estabilidade de Medicamentos
Eritrócitos/citologia
Eritrócitos/efeitos dos fármacos
Eritrócitos/metabolismo
Fibrinólise/efeitos dos fármacos
Metformina/metabolismo
Metformina/farmacologia
Microscopia de Contraste de Fase
Tempo de Tromboplastina Parcial
Tempo de Protrombina
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biocompatible Materials); 0 (Sulfanilamides); 0 (sulfenamide); 21240MF57M (sulfanilamide); 9100L32L2N (Metformin); UR1SAB295F (Sulfamerazine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE


  7 / 8307 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29049216
[Au] Autor:Zhang ZH; Zhang JW; He P; Zhou Y; Sun CY
[Ad] Endereço:aDepartment of Infectious Diseases bDepartment of Geriatric Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
[Ti] Título:Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients.
[So] Source:Medicine (Baltimore);96(42):e8256, 2017 Oct.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Portal vein thrombosis (PVT) is a rare but serious complication in the decompensated stage of cirrhosis, and recurrent upper gastrointestinal bleeding and refractory ascites can occur in such patients. In decompensated cirrhotic patients, the application of conventional anticoagulant therapy is limited due to severe coagulation disorders, thrombocytopenia, and history of gastrointestinal bleeding.In this study, we sought to investigate the effect of fondaparinux on acute PVT in decompensated cirrhotic patients.Patients were treated with fondaparinux (2.5 mg, q 24 h, subcutaneously) in the region of the umbilicus for conventional liver protection, after a clear diagnosis was made and contraindications such as active bleeding were ruled out. Other anticoagulants and circulation-improving drugs were not administered. Platelet count, prothrombin time, international normalized ratio, D dimer (DD), and liver function were measured. Furthermore, portal vein color Doppler ultrasound was performed every 7 days while patients were treated with fondaparinux and after portal vein recanalization.The portal vein was recanalized in all patients after treatment (P = .018). The decline in DD had a predictive value for portal vein recanalization (P = .018). No side effects such as bleeding or thrombocytopenia occurred in any of the patients (P > .05).Selective factor Xa inhibitor fondaparinux is effective and safe for acute PVT in decompensated cirrhotic patients.
[Mh] Termos MeSH primário: Inibidores do Fator Xa/administração & dosagem
Cirrose Hepática/complicações
Polissacarídeos/administração & dosagem
Veia Porta/diagnóstico por imagem
Trombose Venosa/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Feminino
Produtos de Degradação da Fibrina e do Fibrinogênio/análise
Seres Humanos
Coeficiente Internacional Normatizado
Cirrose Hepática/sangue
Cirrose Hepática/tratamento farmacológico
Masculino
Meia-Idade
Contagem de Plaquetas
Veia Porta/cirurgia
Valor Preditivo dos Testes
Tempo de Protrombina
Resultado do Tratamento
Ultrassonografia Doppler/métodos
Procedimentos Cirúrgicos Vasculares/métodos
Trombose Venosa/etiologia
Trombose Venosa/cirurgia
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Factor Xa Inhibitors); 0 (Fibrin Fibrinogen Degradation Products); 0 (Polysaccharides); 0 (fibrin fragment D); J177FOW5JL (fondaparinux)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171122
[Lr] Data última revisão:
171122
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171020
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008256


  8 / 8307 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28930850
[Au] Autor:Yang L; Wang HH; Wei FS; Ma LX
[Ad] Endereço:aDepartment of Gynecology and Obstetrics, The First Affiliated Hospital of Nanchang University, Nanchang bDepartment of Anesthesiology, Xinyu People's Hospital, Xinyu cDepartment of Anesthesiology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P.R. China.
[Ti] Título:Evaluation of acute normovolemic hemodilution in patients undergoing intracranial meningioma resection: A quasi-experimental trial.
[So] Source:Medicine (Baltimore);96(38):e8093, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to evaluate the safety of acute normovolemic hemodilution (ANH) for patients undergoing intracranial meningioma resection.Eighty patients (aged 48-65 years) with American Society of Anesthesiologists physical status I-II undergoing intracranial meningioma resection were included in this prospective observational study. The patients were randomly divided into group A (ANH group), which underwent a combination of ANH and intraoperative cell salvage (ICS), and group B (control group), which underwent ICS alone. The study parameters were recorded as baseline values before blood drainage (T0), after blood drainage (T1), and before (T2) and after (T3) retransfusion in group A. Whereas in group B, the same parameters were measured 10 minutes after anesthesia induction (T0), before surgery (T1), and before (T2) and after (T3) transfusion of autologous blood.When intraoperative blood loss was <2000 mL, the mean volume of homologous blood transfused in group A patients was 100.8 ±â€Š82.3 mL, compared with the 190.0 ±â€Š91.8 mL in group B. Reduction in homologous blood used in group A was statistically significant (P < .05). In group B, 15.1% patients received homologous blood, whereas only 5.9% patients received homologous blood in group A. The difference in heart rate between both groups at different time points was statistically nonsignificant (P > .05). The mean hemoglobin and hematocrit levels at T1 and T2 in group A were lower than in group B (P < .05). The prothrombin time and activated partial thromboplastin time in both groups were prolonged significantly after T2 (all P < .05), but were all within normal range. There were no significant differences in postoperative hospital stay, mortality, and postoperative infection between the 2 groups.For patients undergoing excision of intracranial meningioma, ANH is an effective procedure to reduce the need for allogeneic transfusions.
[Mh] Termos MeSH primário: Hemodiluição/métodos
Neoplasias Meníngeas/cirurgia
Meningioma/cirurgia
[Mh] Termos MeSH secundário: Idoso
Perda Sanguínea Cirúrgica
Transfusão de Sangue
Feminino
Hematócrito
Hemodiluição/efeitos adversos
Hemodinâmica
Hemoglobinometria
Seres Humanos
Masculino
Neoplasias Meníngeas/fisiopatologia
Meningioma/fisiopatologia
Meia-Idade
Tempo de Tromboplastina Parcial
Estudos Prospectivos
Tempo de Protrombina
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171015
[Lr] Data última revisão:
171015
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170921
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008093


  9 / 8307 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28930835
[Au] Autor:Hernaningsih Y; Akualing JS
[Ad] Endereço:aDepartment of Clinical Pathology, Faculty of Medicine Universitas Airlangga, Dr. Soetomo General Hospital, Surabaya, Jawa Timur bClinical Pathology Laboratory, Tobelo General Hospital, North Halmahera, Indonesia.
[Ti] Título:The effects of hemolysis on plasma prothrombin time and activated partial thromboplastin time tests using photo-optical method.
[So] Source:Medicine (Baltimore);96(38):e7976, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hemolysis is the most common reason why coagulation test samples are rejected. However, the effects of hemolysis on plasma prothrombin time (PPT) and activated partial thromboplastin time (APTT) are rarely investigated and the results are controversial. This research aims to analyze the effects of hemolysis on PPT and APPT using the photo-optical method.Nonhemolyzed citrate blood samples (n = 30) with normal PPT and APTT underwent 2-step mechanical lysis and then hemoglobin level measurement was carried out at each step. The first lysis was mild to moderate resulting in a hemoglobin level of <0.8 g/dL. These samples were labeled as group 1. The second step showed more severe lysis, which resulted in a plasma hemoglobin level of ≥0.8 g/dL. These samples were labeled as group 2. Analysis was carried out on the PPT and APTT differences between the 2 groups and baseline, as well as between group 1 and group 2 using repeated-measures analysis of variance (ANOVA). The effects of hemolysis were analyzed using linear regression. Receiver operating characteristic (ROC) curve analysis was performed to determine the cut-off value in PPT and APTT.Significantly shorter APTT was measured for group 1 than baseline, (P = .000), group 2 than baseline (P = .000), and group 2 than group 1 (P = .003). With regard to PPT results, those for group 1 were significant shorter than baseline (P = .002), while those for group 2 were significantly longer than group 1 (P = .000). In the correlation assay, the level of hemolysis revealed a mildly significant correlation to APTT (R = 0.245; P = .02). Cut-off value for PPT was 1.55 g/dL (100% sensitivity and 87.9% specificity), while the value for APTT was 0.95 g/dL (75% sensitivity and 62.5% specificity).Not all hemolyzed samples should be rejected for PPT and APTT tests using photo-optical methods.
[Mh] Termos MeSH primário: Hemólise/fisiologia
Tempo de Tromboplastina Parcial/normas
Tempo de Protrombina/normas
[Mh] Termos MeSH secundário: Análise de Variância
Seres Humanos
Modelos Lineares
Tempo de Tromboplastina Parcial/métodos
Tempo de Protrombina/métodos
Curva ROC
Valores de Referência
Sensibilidade e Especificidade
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171015
[Lr] Data última revisão:
171015
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170921
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007976


  10 / 8307 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28844387
[Au] Autor:Nong W; Zhao A; Wei J; Lin X; Wang L; Lin C
[Ad] Endereço:Guangxi Colleges and Universities Key Laboratory of Applied Chemistry Technology and Resource Development, School of Chemistry & Chemical Engineer in Guangxi University, Nanning 530004, China.
[Ti] Título:Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
[So] Source:Bioorg Med Chem Lett;27(18):4506-4511, 2017 09 15.
[Is] ISSN:1464-3405
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Ten new cinnamic acid derivatives containing a 2-aminothiazole substructure were designed and synthesized. This series of compounds exhibited good thermostabilities as demonstrated by thermogravimetric analysis. In coagulation assays (prothrombin time, activated partial thromboplastin time and thrombin time) in vitro, most compounds demonstrated excellent activities to promote blood coagulation. Among the studied series, compounds N1, N4, N5 and W5 exhibited a significant coagulation activity. Further studies indicated that compound N5 (IC =1.87µmol/L) displayed the most suitable efficacy of promoting platelet aggregation than the clinically used haemostatic drug etamsylate (IC =46.22µmol/L). Furthermore, the relationship between the functional groups of the compounds and the corresponding blood coagulant activity was explored in this study.
[Mh] Termos MeSH primário: Amidas/farmacologia
Cinamatos/farmacologia
Hemostáticos/farmacologia
Inibidores da Agregação de Plaquetas/farmacologia
Tiazóis/farmacologia
[Mh] Termos MeSH secundário: Amidas/síntese química
Amidas/química
Coagulação Sanguínea/efeitos dos fármacos
Cinamatos/síntese química
Cinamatos/química
Relação Dose-Resposta a Droga
Hemostáticos/síntese química
Hemostáticos/química
Seres Humanos
Estrutura Molecular
Tempo de Tromboplastina Parcial
Inibidores da Agregação de Plaquetas/síntese química
Inibidores da Agregação de Plaquetas/química
Tempo de Protrombina
Relação Estrutura-Atividade
Tiazóis/química
Tempo de Trombina
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Amides); 0 (Cinnamates); 0 (Hemostatics); 0 (Platelet Aggregation Inhibitors); 0 (Thiazoles); 5K8WKN668K (2-aminothiazole); U14A832J8D (cinnamic acid)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171125
[Lr] Data última revisão:
171125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170829
[St] Status:MEDLINE



página 1 de 831 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde